High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden

European Journal of Haematology

Volumn 92, Issue 5, 2014, Pages 377-381

  Kozlowski, Piotr ^a   Åström, Maria ^a   Ahlberg, Lucia ^b   Bernell, Per ^c   Hulegårdh, Erik ^d   Hägglund, Hans ^c   Karlsson, Karin ^e   Markuszewska Kuczymska, Alicja ^f   Tomaszewska Toporska, Beata ^e   Smedmyr, Bengt ^g   Amini, Rose Marie ^g   Hallböök, Helene ^g  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Department of Hematology and Coagulation Sahlgrenska University ^*  (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antineoplastic combined chemotherapy protocols; Precursor T cell lymphoblastic leukemia lymphoma; Stem cell transplantation; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; BETAMETHASONE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; REMISSION; SURVIVAL; SWEDEN;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETAMETHASONE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; SWEDEN; TRANSPLANTATION, HOMOLOGOUS; VINCRISTINE;

EID: 84898801134     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12269     Document Type: Article

References (15)

1. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009;114:5136-45.
2. Gokbuget N, Kneba M, RaffT, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868-76.
3. Hallbook H, Simonsson B, Ahlgren T, et al. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol 2002;118:748-54.
4. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-61.
5. Juliusson G, Karlsson K, Hallbook H. Population-based analyses in adult acute lymphoblastic leukemia. Blood 2010;116:1011; author reply 2.
6. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788-801.
7. Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, Shah PS, Beyene J, Sung L. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011;25:1232-8.
8. Kozlowski P, Astrom M, Ahlberg L, et al. High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007. Haematologica 2012;97:1414-21.
9. Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012;120:2032-41.
10. Bakr M, Rasheed W, Mohamed SY, et al. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012;18:1897-904.
11. Shimizu H, Handa H, Hatsumi N, Takada S, Saitoh T, Sakura T, Miyawaki S, Nojima Y. Distinctive disease subgroups according to differentiation stages in adult patients with T-cell acute lymphoblastic leukemia. Eur J Haematol 2013;90:301-7.
12. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008;111:1827-33.
13. Faderl S, Thomas DA, O'Brien S, et al. Augmented Hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk 2011;11:54-9.
14. Ribera JM. Advances in acute lymphoblastic leukemia in adults. Curr Opin Oncol 2011;23:692-9.
15. Toft N, Birgens H, Abrahamsson J, et al. Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 2013;90:404-12.